Daiichi Sankyo is a global pharmaceutical company based in Tokyo, Japan, with a focus on discovering and developing innovative therapies for a wide range of diseases and disorders.
The company was formed in 2005 through the merger of two leading Japanese pharmaceutical companies, Daiichi Pharmaceutical Company, and Sankyo Company, Limited.
Daiichi Sankyo’s main areas of research and development include cardiovascular and metabolic diseases, oncology, and neuroscience.
Some of its key products include the anticoagulant drug Pradaxa, the anti-hypertensive drug Azor, and the anti-cancer drug DS-8201.
The company has a strong presence in Asia, Europe, and North America, and is committed to delivering innovative treatments that improve the health and well-being of patients around the world.